



September 11, 2008

MannKind Corporation to Host Webcast Analyst Day September 16, 2008

Company To Review Data from First Pivotal Phase 3 Clinical Trial

VALENCIA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it will host an analyst day for the investment community to review clinical results from Phase 3 and other clinical trials of the company's Technosphere® Insulin System. The meeting will take place on Tuesday, September 16, 2008 from 9 a.m. to 11 a.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit the MannKind Corporation web site at <http://www.mannkindcorp.com>.

Mr. Al Mann and other members of MannKind's management will review the Phase 3 data, and the meeting will also feature John ("Jack") E. Gerich, M.D., a world renowned diabetologist and expert in the physiology of diabetes and glucose metabolism. Dr. Gerich is professor of medicine and physiology and director of the clinical research center at the University of Rochester School of Medicine.

About the Technosphere® Insulin System

MannKind's investigational inhaled insulin product consists of its proprietary Technosphere® particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using MannKind's proprietary MedTone inhaler. A long sought-after goal in the treatment of diabetes has been to produce a profile of insulin levels in the bloodstream that closely mimics the normal human physiologic insulin response. In clinical studies to date, the Technosphere® Insulin System has been consistently observed to produce peak insulin levels within 12-14 minutes of inhalation, which approximates the early insulin secretion normally seen in healthy individuals following the beginning of a meal. MannKind believes that the ability to produce a better approximation of normal insulin physiology translates into better glucose control, thereby giving this investigational product potential clinical and commercial advantages.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes Technosphere® Insulin, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit <http://www.mannkindcorp.com>.

SOURCE MannKind Corporation

CONTACT: Matthew J. Pfeffer, Corporate Vice President, Chief Financial Officer of MannKind Corporation, +1-661-295-4784, mpfeffer@mannkindcorp.com

Web site: <http://www.mannkindcorp.com>